Detection of mRNA of Telomerase Protein in Benign Naevi and Melanomas Using RNAscope.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
11
8
2018
medline:
24
11
2020
entrez:
11
8
2018
Statut:
ppublish
Résumé
Telomerase is reactivated in most cancers and is possibly an early driver event in melanoma. Our aim was to test a novel in situ hybridization technique, RNAscope, for the detection of human telomerase reverse transcriptase (hTERT) mRNA in archival formalin-fixed, paraffin-embedded (FFPE) tissue and to compare the mRNA expression of melanomas and benign naevi. Furthermore, we wanted to see if hTERT mRNA could be a diagnostic or prognostic marker of melanoma. In situ hybridization for the detection of hTERT mRNA was performed on FFPE tissue of 17 melanomas and 13 benign naevi. We found a significant difference in the expression of hTERT mRNA between melanomas and benign naevi (P<0.001) and the expression of hTERT mRNA correlated with Breslow thickness (ρ=0.56, P=0.0205) and the Ki67 proliferation index (ρ=0.72, P=0.001). This study showed that RNAscope was a reliable in situ hybridization method for the detection of hTERT mRNA in FFPE tissue of melanomas and benign naevi. hTERT mRNA was more abundantly expressed in melanomas compared with benign naevi, but cannot be used solely as a diagnostic marker due to an overlap in expression. The hTERT mRNA expression in melanomas correlated with the prognostic markers Breslow thickness and the Ki67 index indicating a prognostic potential of hTERT mRNA.
Identifiants
pubmed: 30095463
doi: 10.1097/PAI.0000000000000690
pii: 00129039-202001000-00006
doi:
Substances chimiques
Neoplasm Proteins
0
RNA, Messenger
0
RNA, Neoplasm
0
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-41Références
Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527.
Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol. 2006;19(S2):S34–S40.
Ramirez RD, D’Atri S, Pagani E, et al. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma. Neoplasia. 1999;1:42–49.
Miracco C, Margherita De Santi M, Schurfeld K, et al. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity. Br J Dermatol. 2002;146:399–408.
Carvalho L, Lipay M, Belfort F, et al. Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg. 2006;59:961–968.
Muller H. The remaking of chromosomes. Collecting Net. 1938;13:181–198.
McClintock B. The stability of broken ends of chromosomes in Zea mays. Genetics. 1941;26:234–282.
Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A. 1988;85:6622–6626.
Watson JD. Origin of concatemeric T7 DNA. Nat New Biol. 1972;239:197–201.
Olovnikov AM. A theory of marginotomy. J Theor Biol. 1973;41:181–190.
Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458–460.
Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
Kim N, Piatyszek M, Prowse K, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015.
Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010;11:319–330.
Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43 (pt 1):405–413.
Greider CW, Blackburn EH. The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell. 1987;51:887–898.
Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59:521–529.
Meena J, Lenhard Rudolph K, Günes CGhadimi BM, Ried T. Telomere dysfunction, chromosomal instability and cancer. Recent Results in Cancer Research (Vol 200). New York: Springer (LLC); 2015:61–79.
Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature. 1989;337:331–337.
Shippen-Lentz D, Blackburn EH. Functional evidence for an RNA template in telomerase. Science. 1990;247:546–552.
Yu G-L, Bradley JD, Attardi LD, et al. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature. 1990;344:126–132.
Lingner J, Hughes TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science. 1997;276:561–567.
Avilion AA, Piatyszek MA, Gupta J, et al. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 1996;56:645–650.
Yan P, Benhattar J, Seelentag W, et al. Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol. 2004;121:391–397.
Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14:22–29.
Vagner J, Steiniche T, Stougaard M. In-situ hybridization-based quantification of hTR: a possible biomarker in malignant melanoma. Histopathology. 2015;66:747–751.
Nielsen PS, Riber-Hansen R, Raundahl J, et al. Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions. Arch Pathol Lab Med. 2012;136:627–634.
Abedalthagafi MS, Bi WL, Merrill PH, et al. ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet. 2015;208:345–350.
Wu G, Barnhill RL, Lee S, et al. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. Mod Pathol. 2016;29:359–369.
Fullen DR, Zhu W, Thomas D, et al. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue. J Cutan Pathol. 2005;32:680–684.
Ukpo OC, Flanagan JJ, Ma XJ, et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011;35:1343–1350.
Brown J, Buckle VBridger JM, Volpi EV. Detection of nascent RNA transcripts by fluorescence in situ hybridization. Fluorescence In Situ Hybridization (FISH) (Vol 659). New York: Humana Press; 2010:33–50.
Zhang F, Cheng D, Wang S, et al. Human specific regulation of the telomerase reverse transcriptase gene. Genes. 2016;7:7.
Bollmann FM. Physiological and pathological significance of human telomerase reverse transcriptase splice variants. Biochimie. 2013;95:1965–1970.
Ducrest AL, Szutorisz H, Lingner J, et al. Regulation of the human telomerase reverse transcriptase gene. Oncogene. 2002;21:541–552.
Akincilar SC, Unal B, Tergaonkar V. Reactivation of telomerase in cancer. Cell Mol Life Sci. 2016;73:1659–1670.
Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 2001;29:4818–4825.
Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687–701.
Chou S-J, Chen C-M, Harn H-J, et al. Detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma. J Surg Res. 2001;99:75–83.